DPP-IV inhibitor, teneligliptin, reduces atherosclerosis progression in apolipoprotein E (ApoE) knockout mice by alleviating inflammation and oxidative stress in both the vasculature and PVAT [238]. Here, APOE is linked to atherosclerosis.